Media coverage about Lexicon Pharmaceuticals (NASDAQ:LXRX) has trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Lexicon Pharmaceuticals earned a news impact score of 0.12 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.5568806108425 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news headlines that may have effected Accern’s scoring:

Lexicon Pharmaceuticals (NASDAQ:LXRX) traded up $0.77 during mid-day trading on Friday, reaching $9.81. The company had a trading volume of 1,026,600 shares, compared to its average volume of 804,359. Lexicon Pharmaceuticals has a one year low of $8.07 and a one year high of $18.00. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.66 and a quick ratio of 1.85.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative return on equity of 111.68% and a negative net margin of 165.69%. The company had revenue of $26.94 million during the quarter, compared to analyst estimates of $27.97 million. During the same quarter last year, the company earned ($0.35) EPS. The firm’s revenue for the quarter was down 2.8% on a year-over-year basis. equities research analysts forecast that Lexicon Pharmaceuticals will post -1.49 earnings per share for the current fiscal year.

A number of research analysts have recently commented on LXRX shares. Zacks Investment Research cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Wedbush restated an “outperform” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, October 5th. BidaskClub cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $21.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 17th. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $28.75.

COPYRIGHT VIOLATION NOTICE: “Lexicon Pharmaceuticals (LXRX) Receives Daily Media Impact Rating of 0.12” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/11/lexicon-pharmaceuticals-lxrx-receives-daily-media-impact-rating-of-0-12.html.

In other Lexicon Pharmaceuticals news, insider Lonnel Coats bought 30,000 shares of Lexicon Pharmaceuticals stock in a transaction on Friday, September 15th. The stock was acquired at an average price of $12.54 per share, with a total value of $376,200.00. The purchase was disclosed in a document filed with the SEC, which is available at this link. 5.77% of the stock is owned by company insiders.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Insider Buying and Selling by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Stock Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.